EC145

DRUG3 trials

Sponsors

Endocyte

Conditions

Non Small Cell Lung CancerOvarian CancerSolid Tumors

Phase 2

Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)

CompletedNCT01002924

EndocyteSolid Tumors

Start: 2009-12-31End: 2013-12-11Updated: 2021-04-08

Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

CompletedNCT01577654

EndocyteNon Small Cell Lung Cancer

Start: 2011-03-31End: 2015-08-31Updated: 2021-04-01

Phase 3

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

TerminatedNCT01170650

EndocyteOvarian Cancer

Start: 2011-04-22End: 2015-09-08Updated: 2021-09-30

Related Papers

Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m<sup>2</sup> versus 40 mg/m<sup>2</sup> in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

Journal of Gynecologic Oncology2020-11-127 citations

Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer

EJNMMI Research2020-04-0839 citations